Comparing two ways to treat paroxysmal atrial fibrillation with catheter ablation
Compares pulse field ablation with cryoablation in adults with paroxysmal atrial fibrillation.
Plain-language title generated from the registry record
Registry title: The Effect of Pulse Field Ablation on Atrial Mechanics in Catheter Ablation of Paroxysmal Atrial Fibrillation
Key facts
- Where
- Paris, FranceSee the site
Where in France
- Dr Mikael LaredoParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT06557876
- Record updated
- 2 June 2026
- Original description
The goal of this clinical trial is to compare the effect of pulmonary vein isolation on atrial function between pulse-field and cryoablation in patients over the age of 18 with paroxysmal atrial fibrillation. The main question it aims to answer is:Read full original descriptionShow less
The Effect of Pulse Field Ablation on Atrial Mechanics Assessed by MRI and on Patient-related Outcomes in Catheter Ablation of Paroxysmal Atrial Fibrillation
The goal of this clinical trial is to compare the effect of pulmonary vein isolation on atrial function between pulse-field and cryoablation in patients over the age of 18 with paroxysmal atrial fibrillation. The main question it aims to answer is:
• Is catheter ablation energy (pulse field ablation) revealing a better preservation of the atrial function architecture than with conventional catheter ablation technologies ?
Participants will performed 2 IRMs with injection and completed Quality of Life Questionnaires. They participate in the study for 4 months.
Researchers will compare 2 arms:
* Pulse-Field Ablation * Cryoablation
Inclusion: Patient age ≥ 18; Established diagnosis of paroxysmal fibrillation, with a I/IIa/IIb indication for catheter ablation (ESC 2020 guidelines); Episode of AF documented by ECG within the last 12 months; Patient able to give written informed consent; If female of childbearing potential, have a negative serum pregnancy test and using effective contraception; Be affiliated with a French social security system or entitled.
Exclusion: Previous ablation in the left atrium; Previous heart surgery; Participation in another interventional study or being in the exclusion period at the end of a previous study; Significant valvular heart disease defined as any moderate (grade 3) or severe (grade 4) mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis, tricuspid regurgitation, or tricuspid stenosis; Contraindication to perform MRI or using the DOTAREM™ contrast product (pacemaker, defibrillator, foreign body or prosthesis, old generation heart valves, old generation ferromagnetic vascular surgical clips, percutaneous devices for endocranial aneurysms, neurosimulator, cochlear implants, automated injection device such as insulin pump, and more generally any non-removable electronic device, severe kidney disease with GFR < 30 mL/min, documented hypersensitivity to gadoteric acid or to excipients, severe claustrophobia); Non-paroxysmal atrial fibrillation; Contraindication to oral anticoagulation; Intracardiac thrombus; Patient on AME (state medical aid); Pregnant or breast-feeding female; Patient protected by law (guardianship, tutelage measure, deprived of liberty).